Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials.

ABSTRACT:

Background

Patients with multiple sclerosis (PwMS) have an increased risk of infections.

Objectives

To characterize incidence, clinical characteristics, outcomes and risk factors of infections, and serious infections (SIs) in ocrelizumab (OCR)-treated PwMS.

Design

Post-hoc analysis of pooled data from 6155 patients in 13 clinical trials.

Methods

Descriptive analyses of clinical characteristics and outcomes were reported over ⩽14 years. A Poisson Generalized Estimating Equation model was constructed to examine risk factors in a subgroup of patients with longer exposure to OCR (n = 2092).

Results

Over a median (max) treatment period of 3.7 (13.9) years, 420/6155 patients (6.8%) experienced 583 SIs, excluding coronavirus disease 2019. Incidenc

SUBMITTER: Derfuss T 

PROVIDER: S-EPMC11470513 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature